Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary study
Open Access
- 21 August 2008
- journal article
- research article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 10 (4) , R95
Abstract
Introduction: Health care utilisation ('claims') databases contain information about millions of patients and are an important source of information for a variety of study types. However, they typically do not contain information about disease severity. The goal of the present study was to develop a health care claims index for rheumatoid arthritis (RA) severity using a previously developed medical records-based index for RA severity (RA medical records-based index of severity [RARBIS]). Methods: The study population consisted of 120 patients from the Veteran's Administration (VA) Health System. We previously demonstrated the construct validity of the RARBIS and established its convergent validity with the Disease Activity Score (DAS28). Potential claims-based indicators were entered into a linear regression model as independent variables and the RARBIS as the dependent variable. The claims-based index for RA severity (CIRAS) was created using the coefficients from models with the highest coefficient of determination (R2) values selected by automated modelling procedures. To compare our claims-based index with our medical records-based index, we examined the correlation between the CIRAS and the RARBIS using Spearman non-parametric tests. Results: The forward selection models yielded the highest model R2 for both the RARBIS with medications (R2 = 0.31) and the RARBIS without medications (R2 = 0.26). Components of the CIRAS included tests for inflammatory markers, number of chemistry panels and platelet counts ordered, rheumatoid factor, the number of rehabilitation and rheumatology visits, and Felty's syndrome diagnosis. The CIRAS demonstrated moderate correlations with the RARBIS with medication and the RARBIS without medication sub-scales. Conclusion: We developed the CIRAS that showed moderate correlations with a previously validated records-based index of severity. The CIRAS may serve as a potentially important tool in adjusting for RA severity in pharmacoepidemiology studies of RA treatment and complications using health care utilisation data.Keywords
This publication has 20 references indexed in Scilit:
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Neurological complications of infliximab.2006
- Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomasAnnals of the Rheumatic Diseases, 2005
- Death rates and causes of death in patients with rheumatoid arthritis: a population‐based studyScandinavian Journal of Rheumatology, 2004
- Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti–tumor necrosis factor therapy in 18,572 patientsArthritis & Rheumatism, 2004
- Predictors of infection in rheumatoid arthritisArthritis & Rheumatism, 2002
- Demyelination occurring during anti-tumor necrosis factor ? therapy for inflammatory arthritidesArthritis & Rheumatism, 2001
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Incidence of Cancer Among Patients With Rheumatoid ArthritisJNCI: Journal of the National Cancer Institute, 1993
- Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study.Annals of the Rheumatic Diseases, 1988